MUMBAI, India, June 27 -- Intellectual Property India has published a patent application (202547058829 A) filed by Green Cross Corporation, Gyeonggi, Republic of Korea, on June 19, for 'pharmaceutical composition comprising heparan n-sulfatase with improved stability.'
Inventor(s) include Yang, Taeseung; Kim, Miroo; Son, Jaewoon; Yoo, Miri; Lee, Miso; and Jin, Dong Kyu.
The application for the patent was published on June 27, under issue no. 26/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to a pharmaceutical composition of a high concentration of heparan N-sulfatase (HNS) with enhanced stability for CNS delivery and a pharmaceutical formulation comprising the same. The pharmaceutical composition and pharmaceutical formulation comprising the same according to the present invention have excellent formulation stability, such as a reduction in turbidity and a significant improvement in purity, which may be useful in enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis type III."
The patent application was internationally filed on Dec. 22, 2023, under International application No.PCT/KR2023/021457.
Disclaimer: Curated by HT Syndication.
